Dr Stacy Loeb
Dr. Stacy Loeb is a Professor of Urology and Population Health at the New York University School of Medicine and the Manhattan Veterans Affairs Medical Center.
Dr. Loeb is an expert in prostate cancer, men’s health and social media with more than 340 peer-reviewed published articles and 10 book chapters.
She currently has grants from the Prostate Cancer Foundation and Department of Defense for her research on prostate cancer.
Dr. Loeb also hosts the Men’s Health Show on Sirius XM US/Canada satellite radio and serves on the American Urological Association Public Media Committee.
- Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”British Journal of Urology International 2012 epub Nov 8. PMID: 24206066Link:
http://www.ncbi.nlm.nih.gov/pubmed/24206066 In light of numerous conflicting recommendations about prostate cancer screening, in August 2013 a multidisciplinary group convened in Melbourne, Australia to create consensus practice guidelines. Key areas of consensus are that level 1 evidence shows that prostate cancer screening saves lives among men ages 50-69, but that biopsy decisions should be made using PSA as part of a multivariable approach and that diagnosis must be uncoupled from treatment.
- Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.“Baseline Prostate-Specific Antigen Testing at a Young Age.”European Urology January 2012; 61: 1-7. PMID: 21862205.Link:
http://www.ncbi.nlm.nih.gov/pubmed/21862205This study reviews the published literature showing that baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Baseline PSA testing should be offered to young men for risk stratification and to guide screening protocols.
- Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?”Journal of Clinical Oncology January 2011; 29: 464.Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374Although number needed to screen (NNS) and number needed to treat (NNT) are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. We developed a model predicting that the NNS in this trial would decrease from 837 at year 10 to 503 at year 12, and NNT would decrease from 29 to 18.
- Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”Journal of Urology, April 2009; 181: 1606.Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059Men ages 75-80 with PSA levels <3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that PSA testing might be safely discontinued for these men.
- Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”Urology, February 2006; 67: 316.Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597In the general US population, the median PSA level is 0.7 ng/ml in the 40’s and 0.9 ng/ml in the 50’s. Young men with a baseline PSA level above the age-specific median are at significantly greater risk of future prostate cancer diagnosis and aggressive disease. Baseline PSA at a young age is a stronger predictor of prostate cancer than race, family history or digital rectal examination.
- Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA.“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”Urology. 2016 Jul 19 epub. PMID: 27450937.Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937
- Loeb S.“Guideline of guidelines: prostate cancer screening.”BJU International 2014 September; 114: 323. PMID: 24981126.Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643
Using a User-Centered Design Framework to Develop a Tailored Sleep Health Improvement Program (SHIP) for Prostate Cancer Patients and Caregivers
The goal of this project is to design and test a new web-based intervention addressing the specific barriers to sleep for prostate cancer patients and caregivers.
Technology-enhanced AcceleRation of Germline Evaluation for Therapy – The TARGET study
The goal of this project is to study the implementation of germline testing for prostate cancer.
Impact of Online Prostate Cancer Information on Health Disparities
The goal of this project is to examine the impact of information on websites and social media platforms on health disparities in prostate cancer.
#ProstateCancer Quantitative and Qualitative Evaluation of Digital Media and Other Communications to Improve Prostate Cancer Advocacy, Research and Management
The goal of this study is to examine prostate cancer digital media and
Optimal Strategy for Conservative Management of Prostate Cancer
The goal of this Career Development Award is to compare alternative
approaches to active surveillance using a Markov model and to design tools
to improve active surveillance.
Prostate Cancer Treatment: Trends and Outcomes Among US Veterans
The goal of this project is to examine prostate cancer treatment trends and
outcomes in the US veteran population.
- Lecture on the Role of Biomarkers in Prostate Cancer Surveillance for the NYU Cancer Center Community Education Series (October 2015)
- Seminar on prostate cancer screening at Laura and Isaac Perlmutter NYU Cancer Center